Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Dose response curves for cells treated with ALK inhibitors crizotinib and ceritinib (Figure 3 A, B) showed that the isogenic A549 EML4-ALK cell line has selective drug sensitivity to ALK ...

Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the ...

Ensartinib doubled median progression-free survival (PFS) over the first-generation ALK inhibitor, with a median PFS of 25.8 months versus 12.7 months, respectively (HR 0.56, 95% CI 0.40-o.

Actually, it has been confirmed that ALK fusion gene inhibitors are surprisingly effective in treating lung cancer possessing the EML4-ALK gene; in August 2011, an ALK fusion gene inhibitor was ...

The company also has NVL-655, an ALK-selective inhibitor for ALK-driven NSCLC. Similar to Zidesamtinib, NLV-655 has brain penetrance, so it should minimize the negative effects on the CNS ...

in TKI pre-treated ALK-positive NSCLC population anticipated by year-end 2025 Report pivotal data for tyrosine kinase inhibitor (TKI) pre-treated patients with advanced ROS1-positive non-small ...